191 related articles for article (PubMed ID: 33513396)
1. The role of regulatory T cells in the pathogenesis and treatment of prostate cancer.
Karpisheh V; Mousavi SM; Naghavi Sheykholeslami P; Fathi M; Mohammadpour Saray M; Aghebati-Maleki L; Jafari R; Majidi Zolbanin N; Jadidi-Niaragh F
Life Sci; 2021 Nov; 284():119132. PubMed ID: 33513396
[TBL] [Abstract][Full Text] [Related]
2. FoxP3
Saleh R; Elkord E
Cancer Lett; 2020 Oct; 490():174-185. PubMed ID: 32721551
[TBL] [Abstract][Full Text] [Related]
3. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer.
Yokokawa J; Cereda V; Remondo C; Gulley JL; Arlen PM; Schlom J; Tsang KY
Clin Cancer Res; 2008 Feb; 14(4):1032-40. PubMed ID: 18281535
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells express Tumor Necrosis Factor Receptor 2 with the highest intensity among CD4
Ghods A; Mehdipour F; Shariat M; Talei AR; Ghaderi A
Mol Immunol; 2021 Sep; 137():52-56. PubMed ID: 34214829
[TBL] [Abstract][Full Text] [Related]
5. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
[TBL] [Abstract][Full Text] [Related]
6. Targeting Interleukin(IL)-30/IL-27p28 signaling in cancer stem-like cells and host environment synergistically inhibits prostate cancer growth and improves survival.
Sorrentino C; Yin Z; Ciummo S; Lanuti P; Lu LF; Marchisio M; Bellone M; Di Carlo E
J Immunother Cancer; 2019 Jul; 7(1):201. PubMed ID: 31366386
[TBL] [Abstract][Full Text] [Related]
7. Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes.
Yan L; Da Silva DM; Verma B; Gray A; Brand HE; Skeate JG; Porras TB; Kanodia S; Kast WM
Prostate; 2015 Feb; 75(3):280-91. PubMed ID: 25399517
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients.
Derhovanessian E; Adams V; Hähnel K; Groeger A; Pandha H; Ward S; Pawelec G
Int J Cancer; 2009 Sep; 125(6):1372-9. PubMed ID: 19533748
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cells in tumor immunity.
Nishikawa H; Sakaguchi S
Int J Cancer; 2010 Aug; 127(4):759-67. PubMed ID: 20518016
[TBL] [Abstract][Full Text] [Related]
10. [Anti-CCR4 mAb and regulatory T cells].
Kurose K; Ohue Y; Oka M
Gan To Kagaku Ryoho; 2013 Sep; 40(9):1150-5. PubMed ID: 24047773
[TBL] [Abstract][Full Text] [Related]
11. Increased infiltration of CCR4-positive regulatory T cells in prostate cancer tissue is associated with a poor prognosis.
Watanabe M; Kanao K; Suzuki S; Muramatsu H; Morinaga S; Kajikawa K; Kobayashi I; Nishikawa G; Kato Y; Zennami K; Nakamura K; Tsuzuki T; Yoshikawa K; Ueda R; Sumitomo M
Prostate; 2019 Oct; 79(14):1658-1665. PubMed ID: 31390096
[TBL] [Abstract][Full Text] [Related]
12. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells.
Degl'Innocenti E; Grioni M; Capuano G; Jachetti E; Freschi M; Bertilaccio MT; Hess-Michelini R; Doglioni C; Bellone M
Cancer Res; 2008 Jan; 68(1):292-300. PubMed ID: 18172322
[TBL] [Abstract][Full Text] [Related]
13. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer.
Kiniwa Y; Miyahara Y; Wang HY; Peng W; Peng G; Wheeler TM; Thompson TC; Old LJ; Wang RF
Clin Cancer Res; 2007 Dec; 13(23):6947-58. PubMed ID: 18056169
[TBL] [Abstract][Full Text] [Related]
14. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
15. CD4+CD25+ regulatory T cells in tumor immunity.
Chen X; Du Y; Lin X; Qian Y; Zhou T; Huang Z
Int Immunopharmacol; 2016 May; 34():244-249. PubMed ID: 26994448
[TBL] [Abstract][Full Text] [Related]
16. Computational Recognition of a Regulatory T-cell-specific Signature With Potential Implications in Prognosis, Immunotherapy, and Therapeutic Resistance of Prostate Cancer.
Ju M; Fan J; Zou Y; Yu M; Jiang L; Wei Q; Bi J; Hu B; Guan Q; Song X; Dong M; Wang L; Yu L; Wang Y; Kang H; Xin W; Zhao L
Front Immunol; 2022; 13():807840. PubMed ID: 35812443
[TBL] [Abstract][Full Text] [Related]
17. [Suppression of tumor antigen-specific T cell immune responses by regulatory T cells].
Shimazu Y; Nishikawa H
Gan To Kagaku Ryoho; 2014 Sep; 41(9):1057-61. PubMed ID: 25248887
[TBL] [Abstract][Full Text] [Related]
18. Roles of regulatory T cells in cancer immunity.
Takeuchi Y; Nishikawa H
Int Immunol; 2016 Aug; 28(8):401-9. PubMed ID: 27160722
[TBL] [Abstract][Full Text] [Related]
19. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer.
Flammiger A; Weisbach L; Huland H; Tennstedt P; Simon R; Minner S; Bokemeyer C; Sauter G; Schlomm T; Trepel M
Eur J Cancer; 2013 Apr; 49(6):1273-9. PubMed ID: 23266046
[TBL] [Abstract][Full Text] [Related]
20. Role of heterogeneous regulatory T cells in the tumor microenvironment.
Wei T; Zhong W; Li Q
Pharmacol Res; 2020 Mar; 153():104659. PubMed ID: 31982490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
